康缘药业跌2.04%，成交额2.41亿元，主力资金净流出2426.61万元

Core Viewpoint - Kangyuan Pharmaceutical's stock price has shown volatility, with a year-to-date increase of 19.60% but a recent decline of 4.68% over the past five trading days and 7.71% over the past twenty days [2] Group 1: Stock Performance - As of September 12, Kangyuan Pharmaceutical's stock price was 16.29 CNY per share, with a market capitalization of 9.223 billion CNY [1] - The stock experienced a trading volume of 2.41 billion CNY and a turnover rate of 2.57% [1] - The company has seen a net outflow of 24.27 million CNY in principal funds, with large orders showing a buy of 56.96 million CNY and a sell of 80.70 million CNY [1] Group 2: Financial Performance - For the first half of 2025, Kangyuan Pharmaceutical reported a revenue of 1.642 billion CNY, a year-on-year decrease of 27.36%, and a net profit attributable to shareholders of 142 million CNY, down 46.36% year-on-year [2] - The company has distributed a total of 949.8 million CNY in dividends since its A-share listing, with 345 million CNY distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Kangyuan Pharmaceutical was 34,600, a decrease of 15.24% from the previous period [2] - The average circulating shares per person increased by 17.98% to 16,371 shares [2] - Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 14.0379 million shares, a decrease of 9.89 million shares from the previous period [3]